Abingworth has held a final close of Abingworth Bioventures VII at $315 million, surpassing its initial target of $300 million. The fund, which is the firm’s twelfth, will invest in life sciences companies based in Europe and the US. It will invest across all stages of development, including early and late-stage venture, clinical co-development, VIPEs and public equities.
Abingworth Bioventures VI previously closed at £225 million in February 2014.
Asante Capital Group provided placement agent services to ABV VII and Goodwin Proctor acted as legal counsel.